Neurotolerability of gadobenate dimeglumine: Evaluation of brain dopamine concentration in freely moving rats by microdialysis

Investigative Radiology

Volumn 34, Issue 8, 1999, Pages 543-547

  La Noce, Anna ^a   Frigeni, Viviana ^a   Filatori, Isabella ^a   Danieli, Angelo ^a   Tirone, Piero ^a  

^a Bracco SpA   (Italy)

Author keywords

Brain microdialysis; Dopamine; Gadobenate dimeglumine; Neurotolerability

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIDOL; HOMOVANILLIC ACID; NEUROTRANSMITTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTRAST ENHANCEMENT; DOPAMINE BRAIN LEVEL; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; REFERENCE VALUE;

EID: 0032769172     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199908000-00008     Document Type: Article

References (22)

1. Uggeri F, Aime S, Anelli PL, et al. Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln=Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-Carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8, 11-triazatridecan-13-oato(5-)]gadolinate(2-) in a mixture with its enantiomer. Inorganic Chem 1995;34:633-642.
2. de Haën C, Gozzini L. Soluble-type hepatobiliary contrast agents for MR imaging. J Magn Reson Imaging 1993;3:179-186.
3. Davies A, de Haën C. Gadobenic acid dimeglumine salt. Drugs of the Future 1991;16:1001-1003.
4. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine: An overview. Invest Radiol 1998;33:798-809.
5. La Noce A, Miragoli L, Samuelli G, Tirone P. An experimental study on the neurotolerability of gadobenate dimeglumine in a rat model of focal brain ischemia. Invest Radiol 1996;31:550-555.
6. La Noce A, Frigeni V, Demicheli F, Miragoli L, Tirone P. Neurotolerability of gadobenate dimeglumine in a rat model of focal brain ischemia: EEG evaluation. Invest Radiol 1999;34:262-267.
7. Morris TW, Ekholm SE, Prentice LI. The effects of gadolinium-DTPA and -DOTA on neural metabolism. Invest Radiol 1991;26:1087-1090.
8. Allard M, Caillé LM, Bonnemain B, Meyer D, Simonnet G. Action of gadolinium complexes on different enzyme systems. Acta Radiol (Suppl) 1986;369:572-574.
9. Weiner N, Molinoff PB. Catecholamines. In: Siegel GJ, ed. Basic neurochemistry. New York: Raven Press, 1989:233-251.
10. Mohr JP, Gautier JC, Hier D, Stein RW. Middle cerebral artery. In: Barnett HJM, Stein BM, Mohr JP, Yatsu FM, eds. Stroke, vol. 1: Pathophysiology, diagnosis and management. New York: Churchil Livingstone, 1986:377-450.
11. Ungerstedt U. Introduction to intracerebral microdialysis. In: Robinson TE, Justice JB, eds. Microdialysis in the neurosciences. New York: Elsevier, 1991:3-18.
12. Benveniste H, Hansen AJ. Practical aspects of using microdialysis for determination of brain interstitial concentrations. In: Robinson TE, Justice JB, eds. Microdialysis in the neurosciences. New York: Elsevier, 1991:81-97.
13. Westerink BHC, Justice JB Jr. Microdialysis compared with other in vivo release models. In: Robinson TE, Justice JB, eds. Microdialysis in the neurosciences. New York: Elsevier, 1991:23-40.
14. Westerink BHC, Tuntler J, Damsma G Rollema H, Vries JB. The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. Naunyn-Schmiedeberg's Arch Pharmacol 1987;336:502-507.
15. Luzzani F, Cipolla P, Pélaprat ML, et al. Brain penetration and neurological effects of gadobenate dimeglumine in the rat. Acta Radiologica 1997;38:268-272.
16. Kendrick KM. Microdialysis measurement of in vivo neuropeptide release. J Neurosci Methods 1990;34:35-46.
17. Kalivas PW, Duffy P. A comparison of axonal and somatodendritic dopamine release using in vivo dialysis. J Neurochem 1991;56: 961-967.
18. Ungerstedt U. Measurement of neurotransmitter release by intracranial dialysis. In: Marsden CA, ed. Measurement of neurotransmitter release in vivo. New York: John Wiley & Son Ltd, 1984:81-105.
19. Zetterström T, Sharp T, Collin AK, Ungerstedt U. In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur J Pharmacol 1988;148:327-334.
20. Carlsson A, Sharp T, Zetterström T, Ungerstedt U. Determination of dopamine and its metabolites in small volumes of rat brain dialysates using small-bore liquid chromatography with electrochemical detection. J Chromatogr 1986;368:299-308.
21. Arbuthnott GW, Fairbrother IS, Butcher SP. Brain microdialysis studies on the control of dopamine release and metabolism in vivo. J Neurosci Methods 1990;34:73-81.
22. Georgieva J, Luthman J, Mohringe B, Magnusson O. Tissue and microdialysate changes after repeated and permanent probe implantation in the striatum of freely moving rats. Brain Res Bull 1993; 31:463-470.